Citius Oncology (CTOR) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Citius Oncology (CTOR) has outperformed NeOnc Technologies (NTHI) over the past year, losing 54.8% versus a loss of 73.9%. Citius Oncology is the larger company by market cap ($81.2 million vs $77.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | NTHI |
|---|---|---|
| Share price | $0.7679 | $2.70 |
| Market cap | $81.21M | $77.77M |
| 1-day change | +2.94% | -1.82% |
| YTD return | -23.21% | -67.35% |
| 1-year return | -54.83% | -73.91% |
| EPS (TTM) | $-0.48 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $39.99K |
| Revenue growth (YoY) | — | -51.82% |
| Net income (latest FY) | $-24.76M | $-62.15M |
| Operating margin | — | -145637.52% |
| Net margin | — | -155404.38% |
| 52-week high | $1.95 | $12.00 |
| 52-week low | $0.491 | $2.50 |
| Distance from 52-week high | -60.62% | -77.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +420.90% | +529.63% |
| Average volume | 102.94K | 196.47K |
| Shares outstanding | 105.76M | 28.81M |
| Employees | — | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTOR has outperformed NTHI by 19.1 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CTOR vs NTHI FAQ
Which is bigger, Citius Oncology or NeOnc Technologies?
Citius Oncology (CTOR) is larger, with a market capitalization of $81.21M compared with $77.77M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, CTOR or NTHI?
CTOR returned -54.83% over the past 12 months, compared with -73.91% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.